Drugs / BGB-15025
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04649385 | Mar 2021 → Oct 2025 | neoplasm | BeiGene | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06029127 | Oct 2023 → Dec 2024 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05635708 | Mar 2023 → Dec 2025 overdue | non-small cell lung carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-03-10 | BeOne Medicines | BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 beonemedicines.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-15025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06029127 ↗ |
| Action | Inhibit | “HPK1 Inhibitor BGB-15025” NCT04649385 ↗ |
| Route | Oral | “Administered orally once or twice daily (QD or BID)” NCT04649385 ↗ |
| Target | HPK1 | “HPK1 Inhibitor BGB-15025” NCT04649385 ↗ |